Phase 1 study of tazemetostat in Japanese patients with relapsed or refractory B-cell lymphoma.

ABSTRACT:

Background

Tazemetostat is a selective and orally available inhibitor of enhancer of zeste homolog 2 (EZH2), a histone methyltransferase and epigenetic regulator of cellular differentiation programs. We carried out a phase I study of tazemetostat in Japanese patients with relapsed or refractory B-cell non-Hodgkin-type lymphoma (B-NHL) to evaluate its tolerability, safety, pharmacokinetics, and preliminary antitumor activity.

Methods

Tazemetostat was given orally at a single dose of 800 mg on the first day and 800 mg twice daily (BID: total 1600 mg/d) on following days in a 28-day/cycle manner. Tazemetostat dose-limiting toxicity (DLT) was evaluated up to the end of the first treatment cycle. Archival tumor tissues were analyzed for hotspot EZH2 mutations.

Results

As o

SUBMITTER: Munakata W 

PROVIDER: S-EPMC7935786 | biostudies-literature | 2021 Mar

REPOSITORIES: biostudies-literature